Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-05-24 5:00 pm Purchase | 13D | FOGHORN THERAPEUTICS INC FHTX | Flagship Ventures Fund V L.P. | 16,303,949 22.900% | 3,629,829 (+28.64%) | View |
| 2024-02-14 4:36 pm Sale | 13G | Sigilon Therapeutics Inc. SGTX | Flagship Ventures Fund V L.P. | 0 0.000% | -10,370,369 (Position Closed) | View |
| 2024-02-14 4:19 pm Sale | 13G | Sana Biotechnology Inc. SANA | Flagship Ventures Fund V L.P. | 25,583,551 13.000% | -8,655,467 (-25.28%) | View |
| 2023-07-13 5:00 pm Purchase | 13D | EVELO BIOSCIENCES INC EVLO | Flagship Ventures Fund V L.P. | 7,932,624 42.200% | 7,932,624 (New Position) | View |
| 2023-02-27 5:02 pm Purchase | 13D | Omega Therapeutics Inc. OMGA | Flagship Ventures Fund V L.P. | 29,245,431 53.200% | 3,343,162 (+12.91%) | View |
| 2023-02-14 1:02 pm Purchase | 13G | Codiak BioSciences Inc. CDAK | Flagship Ventures Fund V L.P. | 4,473,969 11.800% | 1,866,666 (+71.59%) | View |
| 2022-06-01 5:01 pm Purchase | 13D | EVELO BIOSCIENCES INC EVLO | Flagship Ventures Fund V L.P. | 50,427,328 46.700% | 27,397,259 (+118.96%) | View |
| 2022-02-14 3:02 pm Purchase | 13G | Sana Biotechnology Inc. SANA | Flagship Ventures Fund V L.P. | 34,239,018 18.100% | 34,239,018 (New Position) | View |
| 2021-08-05 6:43 pm Purchase | 13D | Omega Therapeutics Inc. OMGA | Flagship Ventures Fund V L.P. | 25,902,269 55.400% | 25,902,269 (New Position) | View |
| 2021-02-16 5:08 pm Sale | 13G | Denali Therapeutics Inc. DNLI | Flagship Ventures Fund V L.P. | 2,730,263 2.200% | -5,250,000 (-65.79%) | View |
| 2021-02-16 5:07 pm Purchase | 13G | Codiak BioSciences Inc. CDAK | Flagship Ventures Fund V L.P. | 2,607,303 13.900% | 2,607,303 (New Position) | View |
| 2021-02-16 5:06 pm Purchase | 13G | Sigilon Therapeutics Inc. SGTX | Flagship Ventures Fund V L.P. | 10,370,369 33.200% | 10,370,369 (New Position) | View |
| 2021-02-10 5:15 pm Purchase | 13D | KALEIDO BIOSCIENCES INC KLDO | Flagship Ventures Fund V L.P. | 19,575,710 47.700% | 215,000 (+1.11%) | View |
| 2021-02-04 5:30 pm Purchase | 13D | EVELO BIOSCIENCES INC EVLO | Flagship Ventures Fund V L.P. | 23,030,069 43.900% | 114,310 (+0.50%) | View |
| 2020-10-29 5:00 pm Purchase | 13D | FOGHORN THERAPEUTICS INC FHTX | Flagship Ventures Fund V L.P. | 12,674,120 35.500% | 12,674,120 (New Position) | View |
| 2020-07-01 5:04 pm Purchase | 13D | EVELO BIOSCIENCES INC EVLO | Flagship Ventures Fund V L.P. | 22,915,759 49.700% | 4,682,356 (+25.68%) | View |
| 2020-06-08 4:30 pm Purchase | 13D | KALEIDO BIOSCIENCES INC KLDO | Flagship Ventures Fund V L.P. | 19,360,710 55.000% | 2,000,000 (+11.52%) | View |
| 2020-02-13 4:18 pm Sale | 13G | Denali Therapeutics Inc. DNLI | Flagship Ventures Fund V L.P. | 7,980,263 8.300% | -938,486 (-10.52%) | View |